Supp Figure 2 from Dual Antiangiogenesis Agents Bevacizumab Plus Trebananib, without Chemotherapy, in First-line Treatment of Metastatic Colorectal Cancer: Results of a Phase II Study

Jennifer Mooi,Fiona Chionh,Peter Savas,Jessica Da Gama Duarte,Geoffrey Chong,Stephen Brown,Rachel Wong,Timothy J. Price,Alysson Wann,Effie Skrinos,John M. Mariadason,Niall C. Tebbutt

crossref（2023）

引用 0|浏览11

暂无评分

摘要

Supplementary Fig 2. Change in overall (A) and specific (B) plasma antibody titres against tumour antigens from baseline (D0) to 6 weeks of treatment (6W), n=8 patients.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要